The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.
The NMI Natural and Medical Sciences Institute at the university and its affiliate will use the patents to expand their cell-based research service offerings.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.
The deal expands Evotec's existing CRISPR licenses through the Broad Institute and adds to ERS's list of licensees for its gene editing technology.
The technology is designed to enable more efficient targeted DNA cassette insertion in the engineering of animal models.
The companies are aiming to develop and establish clinical operation for the assays in Japan, where Hitachi said there is growing demand for such tests.
South Korea-based Macrogen has acquired a a non-exclusive research tool license to CRISPR-Cas9 technology.
Qiagen intends to use System Biosciences' ExoQuick technology in its precipitation-based miRcury Exosome Kits.
Pairwise, an agricultural startup using gene editing to address global food challenges, was cofounded by Feng Zhang, David Liu, and Keith Joung.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.